Synthetic biology is a science of designing, altering, and building simple organisms to perform specific therapeutic or industrial utilities. The commercialization or industrialization of biology renders processes quicker, cheaper and reliable. The organisms created are known as genetically modified organisms (GMOs), which do not require a definition that distinguishes it from genetic modifications.
Thermo Fisher Scientific and Agilent Technologies, Inc. – Notable Market Players in Synthetic Biology Market
The synthetic biology market is majorly comprised of top players involving Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, New England Biolabs, Integrated DNA Technologies, Twists Bioscience, Genscript Biotech Corporation, Novozymes A/S, Codexis, Amyris among others.
The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the synthetic biology market:
| Year | News |
| February-2022 | Thermo Fisher Scientific Launched GeneMapper Software that is a flexible genotyping software package that provides DNA sizing and quality allele calls for all Thermo Fisher Scientific electrophoresis-based genotyping. |
| Jan-2022 | The Oncomine BRCA Assay GX is a targeted next-generation sequencing (NGS) assay designed to provide comprehensive amplification of all coding regions of the human BRCA1 and BRCA2 genes, enabling accurate and sensitive detection of various mutation classes. |
| APR-2022 | Agilent Technologies Inc. announced it has expanded CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx as an aid in identifying esophageal squamous cell carcinoma patients for treatment with Bristol Myers Squibb’s PD-1-targeted immunotherapeutic OPDIVO (nivolumab), in combination with fluoropyrimidine and platinum-based chemotherapy or OPDIVO in combination with YERVOY (ipilimumab). These combined treatments provide new hope for patients diagnosed with these cancers. |
| Feb-2021 | Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has completed its previously announced acquisition of Mesa Biotech, Inc., a privately held point-of-care molecular diagnostic company. Mesa Biotech is an important part of our strategy to expand the benefits of molecular diagnostics at the point of care, starting with COVID-19 testing,” said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. “By combining Thermo Fisher’s operational excellence, access to raw materials and existing distribution and sales channels with Mesa’s innovative platform, we can rapidly scale manufacturing volume, drive cost efficiencies and bring much-needed diagnostics to market faster and at greater scale. |
